Full-Time

Director Toxicology

Translational Science

Updated on 9/3/2026

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

201-500 employees

Develops FDA-approved ophthalmic therapies

Compensation Overview

$188.2k - $263.6k/yr

+ Bonus + Stock equity

Irvine, CA, USA

Hybrid

Hybrid work environment with remote work available; based in the Irvine office.

PhD, MD, Doctor of Veterinary Medicine (DVM)

Category
Biology & Biotech

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Requirements
  • A PhD, MD/PhD, DVM, or related degree in Toxicology, Pharmacology, or Biology is required.
  • At least 12 years of experience in pharmaceutical or biopharmaceutical toxicology or pathology is required.
  • Strong knowledge of Good Laboratory Practice and International Council for Harmonisation guidance is required.
  • The candidate must be able to develop comprehensive preclinical safety approaches with internal stakeholders and deliver executive and agency presentations.
  • Experience managing outsourced studies is required.
  • Excellent oral and written communication skills, including writing, reviewing, and editing scientific documents, are required.
  • Strong interpersonal, diplomacy, and positive-influencing abilities are required.
  • Exceptional communication, influencing, and partnering skills are required to drive decision-making within multidisciplinary, matrixed teams.
  • Effective project management skills are required.
  • Strong presentation skills and the ability to provide succinct, strategic, and actionable insights are required.
  • The candidate must be proactive, able to lead work independently, anticipate issues, and identify next steps.
  • An enterprise and entrepreneurial mindset is required.
Responsibilities
  • Serve as a scientific and strategic leader driving team and pipeline development, bridging discovery and clinical development from concept through IND-enabling and early clinical studies.
  • Serve as the subject matter expert in toxicology, safety pharmacology, and nonclinical safety assessment across all company programs.
  • Establish and maintain external partnerships with contract research organizations, academic institutions, and key opinion leaders.
  • Define and drive Good Laboratory Practice safety and toxicology strategies across programs to accelerate programs to first-in-human studies.
  • Oversee Good Laboratory Practice and non-Good Laboratory Practice toxicology and safety pharmacology studies at contract research organizations, ensuring scientific rigor, data integrity, regulatory compliance, animal welfare, standard operating procedures, and technical study requirements.
  • Review and edit study protocols and reports to ensure scientific rigor, regulatory compliance, and high-quality study interpretation.
  • Build out the Toxicology program and bioanalytics and biomarker capacity.
  • Author and review toxicology sections for regulatory submissions, including IND, CTA, NDA/BLA, investigator brochures, and clinical study reports.
  • Represent toxicology in cross-functional program teams and governance forums.
  • Maintain study timelines and ensure nonclinical studies are conducted in accordance with overall program objectives.
  • Assist nonclinical project leaders in integrating and assembling toxicology data for regulatory submissions, including IND, NDA, and BLA submissions.
  • Build strong relationships with internal teams and external partners to support optimal decision-making.
  • Partner with internal experts, including the Innovation Lab and Business Development, for asset evaluation and development strategies, and identify toxicology risks and mitigation strategies.
  • Identify and implement innovative artificial intelligence-driven toxicology approaches, including new approach methodologies, to support regulatory submissions and interactions with regulatory agencies.
Desired Qualifications
  • DABT or ERT certification is preferred.
  • Experience in ophthalmology is preferred.
  • Experience with European Medicines Agency and Food and Drug Administration CTA/IND submissions and regulatory interactions is preferred.
Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

View

Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY, an FDA-approved lotilaner eye drop for Demodex Blepharitis. It works by applying the ophthalmic solution to the eyelids to kill Demodex mites and reduce eyelid inflammation. The company differentiates itself with a focused ocular and infectious diseases portfolio and by pursuing collaborations to advance its pipeline alongside selling approved products. Its goal is to address unmet medical needs, grow its product lineup, and expand into additional indications in eye care and infectious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 XDEMVY sales rose 69% to $173.9 million, raising guidance to $705 million.
  • September 4, 2026 Alkeus closing expands Tarsus into retina, diversifying beyond one product.
  • TP-05 Lyme and TP-04 rosacea trials create multiple shots at new markets.

What critics are saying

  • XDEMVY supplies nearly all revenue; any prescribing slowdown hits 2027 profitability.
  • ALK-001 data arrives second-half 2029, leaving Tarsus exposed to execution risk for years.
  • SG&A reached $150.7 million in Q2 2026, forcing expensive commercialization discipline.

What makes Tarsus Pharmaceuticals unique

  • XDEMVY is the first FDA-approved Demodex blepharitis treatment, launched in 2023.
  • Tarsus built a proprietary ophthalmology platform spanning XDEMVY, IRX-101, and ALK-001.
  • September 4, 2026 closed Alkeus adds Stargardt disease rights and retina credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
Yahoo Finance
Aug 7th, 2026
Tarsus raises 2026 XDEMVY sales outlook to $705M, acquires Alkeus for $450M upfront

Tarsus Pharmaceuticals reported strong Q2 performance for its Demodex blepharitis treatment XDEMVY, with sales rising 69% year-over-year to $173.9 million. The company raised its 2026 sales guidance to $685–$705 million, noting that over 700,000 patients have used the treatment since launch. Tarsus announced plans to acquire Alkeus Pharmaceuticals for $450 million upfront, adding late-stage Stargardt disease therapy ALK-001 to its pipeline. The Phase III NORTHSTAR trial is underway, with top-line results expected in the second half of 2029. The acquisition will expand Tarsus' strategy beyond XDEMVY into retina care. However, the company raised 2026 R&D guidance to $190–$210 million due to increased near-term spending. Profitability could potentially arrive in 2027, subject to acquisition-related costs.

Vision Monday
Aug 7th, 2026
Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half.

Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half. Friday, August 7, 2026 12:24 AM IRVINE, Calif. - Tarsus Pharmaceuticals announced yesterday that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The deal includes an upfront consideration of about $450 million, the companies said, comprising $270 million in cash and $180 million in Tarsus common stock. The pending transaction is expected to close this year, and also includes a milestone of up to $350 million upon potential regulatory approval and first commercial sale. The news was announced along with a strong unaudited financial report that saw total Q2 revenue for Tarsus rise to $173.9 million and first half revenue rise to nearly $336 million. According to the announcement, the planned acquisition of Alkeus represents what Tarsus said is an important step in its long-term strategy to build a leading eyecare company by bringing differentiated medicines to patients with significant unmet needs. The acquisition is expected to expand Tarsus' growing presence in retina, complement the capabilities established through the acquisition of iRenix Medical last month, and add a differentiated phase 3 program potentially addressing Stargardt disease. "From the beginning, our strategy has been to build a leading eyecare company by identifying significant diseases where patients have been starving for innovation and bringing forward medicines with the potential to change the standard of care," said Bobby Azamian, MD, Ph.D., CEO and chairman of Tarsus. "We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease and complements the retina capabilities we are already building through IRX-101. We also have tremendous respect for the Alkeus team and the exceptional work they have done to identify and bring forward an optimal asset to potentially address this blinding disease." Second Quarter and First Half Reporting The acquisition announcement came nearly concurrent with strong unaudited second quarter and first half reporting from Tarsus. Net sales of $173.9 million marked more than 69 percent growth versus last year's Q2 of $102.7 million, with net product sales of XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop designed to treat Demodex blepharitis, serving as a primary revenue driver, as well as what the company said was higher volume and improvements in the gross-to-net discount. Total first-half revenue for the company was reported at nearly $336 million (versus $181 million for the same period last year), with $319.3 million attributed to XDEMVY product sales and $16.7 million attributed to license fees and collaborations. Cost of sales in Q2 were $12.1 million compared with $6.2 million for the same period in 2025, due to manufacturing costs related to Xdemvy, the company said. Research and development expenses totaled $31.0 million compared with $15.6 million for the same period in 2025. Selling, general and administrative expenses were $150.7 million compared with $103.0 million for the same period in 2025. Net loss in the second quarter narrowed to $18.6 million, compared with $20.3 million for the same period in 2025, the company said. As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million. The company also took the further step of increasing 2026 net sales guidance for XDEMVY to $685 million to $705 million. Related to the pending acquisition, Barclays is acting as exclusive financial advisor to Tarsus and Jefferies is acting as exclusive financial advisor to Alkeus. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is acting as legal counsel to Tarsus, and Latham & Watkins LLP is acting as legal counsel to Alkeus.

Central Charts
Aug 6th, 2026
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing to fund Alkeus acquisition

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.

GlobeNewswire
Aug 6th, 2026
Tarsus Pharmaceuticals acquires Alkeus for $450M to advance Stargardt disease treatment

Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront, consisting of $270 million in cash and $180 million in Tarsus stock. The deal includes potential milestone payments of up to $350 million upon regulatory approval and first commercial sale, plus low single-digit royalties. The acquisition adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine for Stargardt disease, an inherited retinal condition affecting over 36,000 people in the US with no FDA-approved treatments. More than 400 individuals have been treated with the drug to date, showing encouraging clinical findings. Top-line Phase 3 NORTHSTAR data are expected in the second half of 2029. The transaction has been approved by both companies' boards and Alkeus stockholders. It is expected to close in 2026, subject to regulatory clearances and customary conditions.

Minichart
Jul 9th, 2026
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance Eye Care with Late-Stage IRX-101 Asset

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has announced a major strategic acquisition, taking over privately held iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. This transaction marks a significant step in Tarsus’ ambition to expand its leadership in the eye care market and could have material implications for the company’s future growth, pipeline development, and share price.